Zacks Investment Research on MSN
RXRX Q2 earnings miss estimates, revenues fall Y/Y, stock down
Recursion Pharmaceuticals RXRX reported a loss of 25 cents per share in the second quarter of 2026, wider than the Zacks ...
Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on ...
For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX-1.32%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results